Codexis, Inc. (CDXS) Sets 52-Week High

May 16, 2018 - By Heather Owens

Codexis, Inc. (NASDAQ:CDXS) Corporate Logo

Big Money Sentiment decreased to 2.17 in 2017 Q4. It has change of 0.03, from 2017Q3’s 2.2. The ratio fall due to Codexis, Inc. positioning: 3 sold and 15 reduced. 12 funds bought positions and 27 increased positions. Investors holded 25.60 million in 2017Q3 but now own 28.02 million shares or 9.42% more.
American Int Group Inc Inc has invested 0% in Codexis, Inc. (NASDAQ:CDXS). Renaissance Technologies Limited Company reported 482,100 shs. Schwab Charles accumulated 84,581 shs. Jpmorgan Chase And stated it has 8,800 shs or 0% of all its holdings. Virtu Fincl Limited Co has 24,209 shs for 0.01% of their capital. Envestnet Asset Management invested in 0% or 1,662 shs. Metropolitan Life Communication stated it has 0% of its capital in Codexis, Inc. (NASDAQ:CDXS). Fmr Limited Liability Corp invested 0% of its capital in Codexis, Inc. (NASDAQ:CDXS). Deutsche Savings Bank Ag owns 107,089 shs for 0% of their capital. Strs Ohio holds 0% or 88,800 shs. 6,594 were accumulated by Parallax Volatility Advisers Limited Partnership. Ameriprise Fincl Inc accumulated 0% or 95,500 shs. National Bank Of New York Mellon Corporation reported 0% of its capital in Codexis, Inc. (NASDAQ:CDXS). Northern Trust invested 0% in Codexis, Inc. (NASDAQ:CDXS). Blackrock Incorporated has invested 0% in Codexis, Inc. (NASDAQ:CDXS).

Codexis, Inc. had 5 insider sales and 0 buys since March 21, 2018. This’s net activity of $1.19 million. BARUCH THOMAS R had sold 25,000 shs worth $276,318 on Wednesday, March 28. KELLEY BERNARD J had sold 10,206 shs worth $124,683 on Wednesday, March 21. $464,384 worth of Codexis, Inc. (NASDAQ:CDXS) shs were sold by WOLF DENNIS P. Another trade for 6,000 shs valued at $62,213 was sold by Smith David V.

Codexis, Inc. (NASDAQ:CDXS) touched yearly high touching $14.11. Our price target is $15.24. reported it on May, 16. It has $751.49 million MC. At $15.24 stock price target, the company valuation changes by $60.12M more.

The stock increased 6.53% or $0.86 during the last trading session, reaching $14.11.Codexis, Inc. has 492,171 shares volume, 17.42% up from normal. CDXS is uptrending and has moved 125.77% since May 16, 2017. CDXS outperformed by 114.22% the S&P500.

Investors wait Codexis, Inc. (NASDAQ:CDXS)’s quarterly earnings on August, 8., as reported by RTT. Analysts predict 76.92 % diference or $-0.03 from the $-0.13 EPS from 2017. -70.00 % EPS growth is what analysts predict. $-0.10 earnings per share was revealed for last quarter.

Codexis, Inc. (NASDAQ:CDXS) Ratings Coverage

Total analysts of 2 have positions in Codexis (NASDAQ:CDXS) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. The firm has $1600 highest while $11.5 is the lowest PT. The average target $13.75 is -2.55% below the last ($14.11) price. Since March 12, 2018 according to StockzIntelligence Inc Codexis has 2 analyst reports. On Wednesday, May 16 Stephens initiated Codexis, Inc. (NASDAQ:CDXS) with “Buy” rating. In Monday, March 12 report H.C. Wainwright maintained the stock with “Buy” rating.

A couple more Codexis, Inc. (NASDAQ:CDXS) news were posted by: which released on May 11, 2018 “Codexis’ (CDXS) CEO John Nicols on Q1 2018 Results – Earnings Call Transcript”, also on May 03, 2018 posted “Codexis to Hold First Quarter 2018 Conference Call on May 10”, the next is “3 High-Growth Stocks That Are Just Getting Started” on May 12, 2018. has article titled “Codexis Reports First Quarter 2018 Financial Results”.

Codexis, Inc. discovers, develops, and sells protein catalysts.The firm is valued at $751.49 million. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable clients to perform chemistry screening.Currently it has negative earnings. The firm also provides protein catalyst screening and protein engineering services.

Codexis, Inc. (NASDAQ:CDXS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: